Vanda Pharmaceuticals (VNDA) Assets Average (2011 - 2026)

Vanda Pharmaceuticals (VNDA) has 16 years of Assets Average data on file, last reported at $461.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 28.39% year-over-year to $461.2 million; the trailing twelve-month figure through Mar 2026 stood at $461.2 million (down 28.39% YoY), and the FY2025 full-year result was $572.6 million, down 12.22% from the prior year.
• Assets Average retreated to $461.2 million in Q1 2026, from $545.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $652.0 million in Q2 2024 to a low of $461.2 million in Q1 2026.
• A 5-year average of $618.3 million and a median of $639.4 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average grew 11.21% in 2022 and retreated 28.39% in 2026, its largest moves.
• Tracing VNDA's Assets Average over 5 years: stood at $628.0 million in 2022, then grew by 2.71% to $645.0 million in 2023, then grew by 0.87% to $650.7 million in 2024, then decreased by 16.23% to $545.0 million in 2025, then declined by 15.38% to $461.2 million in 2026.
• Business Quant data shows VNDA's Assets Average at $461.2 million in Q1 2026, $545.0 million in Q4 2025, and $612.9 million in Q3 2025.